Jazz Pharmaceuticals’ JZP-6 to be Reviewed at a Joint Meeting of the FDA’s Arthritis Advisory Committee and Drug …

Jazz Pharmaceuticals’ JZP-6 to be Reviewed at a Joint Meeting of the FDA’s Arthritis Advisory Committee and Drug …
PALO ALTO, Calif., June 24 /PRNewswire-FirstCall/ — Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that the U.S.
Read more on redOrbit

Jazz Pharmaceuticals’ JZP-6 to be Reviewed at a Joint Meeting of the FDA’s Arthritis Advisory Committee and Drug …
Jazz Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration’s Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee will review JZP-6 for the treatment of fibromyalgia at a joint meeting on August 20, 2010.
Read more on PR Newswire via Yahoo! Finance